- Home
- RERE vs GYRE Comparison
RERE vs GYRE Comparison
Compare RERE & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- GYRE
- Stock Information
- Founded
- RERE 2011
- GYRE 2002
- Country
- RERE China
- GYRE United States
- Employees
- RERE N/A
- GYRE N/A
- Industry
- RERE Other Specialty Stores
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- GYRE Health Care
- Exchange
- RERE Nasdaq
- GYRE Nasdaq
- Market Cap
- RERE 932.6M
- GYRE 755.7M
- IPO Year
- RERE 2021
- GYRE N/A
- Fundamental
- Price
- RERE $4.26
- GYRE $8.34
- Analyst Decision
- RERE
- GYRE Strong Buy
- Analyst Count
- RERE 0
- GYRE 2
- Target Price
- RERE N/A
- GYRE $17.00
- AVG Volume (30 Days)
- RERE 1.4M
- GYRE 90.0K
- Earning Date
- RERE 11-19-2025
- GYRE 11-12-2025
- Dividend Yield
- RERE N/A
- GYRE N/A
- EPS Growth
- RERE N/A
- GYRE N/A
- EPS
- RERE 0.12
- GYRE 0.02
- Revenue
- RERE $2,588,775,650.00
- GYRE $102,189,000.00
- Revenue This Year
- RERE $30.66
- GYRE $15.25
- Revenue Next Year
- RERE $25.12
- GYRE $33.14
- P/E Ratio
- RERE $33.56
- GYRE $178.16
- Revenue Growth
- RERE 27.39
- GYRE N/A
- 52 Week Low
- RERE $2.00
- GYRE $6.11
- 52 Week High
- RERE $4.93
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- RERE 53.70
- GYRE 56.37
- Support Level
- RERE $3.78
- GYRE $7.75
- Resistance Level
- RERE $4.12
- GYRE $8.35
- Average True Range (ATR)
- RERE 0.20
- GYRE 0.41
- MACD
- RERE 0.01
- GYRE 0.02
- Stochastic Oscillator
- RERE 78.83
- GYRE 51.57
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.